Author | Conference | Journal | Organization | Year | DOI
Look for results that meet for the following criteria:
Academic
Publications
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma,10.1007/s11523-011-0172-y,Targeted Oncology,Sumant

Edit
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma   (Citations: 4)
BibTex | RIS | RefWorks Download
With an explosion of available treatments for metastatic renal cell carcinoma (mRCC) in recent years, it is important to recognize that approved targeted therapies fall broadly into only two mechanistic categories. The first category, vascular endothelial growth factor (VEGF)-directed therapies, includes sunitinib, pazopanib, sorafenib and bevacizumab. The second category includes inhibitors of the mammalian target of rapamycin (mTOR), namely everolimus and temsirolimus. A pivotal trial of everolimus supports use of the agent in patients with mRCC refractory to VEGF- tyrosine kinase inhibitors (TKI) therapy, while pivotal data for temsirolimus supports use in poor-prognosis patients as first-line therapy. Multiple reviews exist to delineate the laboratory and clinical development of mTOR inhibitors. This paper will outline the future applications of these therapies. It will explore ongoing trials evaluating combinations of mTOR inhibitors with other targeted therapies, along with sequencing strategies and biomarker discovery efforts. The application of mTOR inhibitors in unique populations is also described.
Journal: Targeted Oncology - TARGET ONCOL , vol. 6, no. 1, pp. 5-16, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...The two-part series also highlights the clinical results achieved with TOR inhibitors in patients with a variety of advanced cancers to date including: renal cancer as reviewed by Kumar Pal and Figlin [29], hematopoietic and lymphoid malignancies as reviewed by Kelly et al. [30], soft tissue sarcoma as reviewed by Vemulapalli et al. [31], pediatric malignancies as reviewed by Cam and Houghton [14] and various other relevant ...

    Eric K. Rowinsky. Targeting the target of rapamycin (TOR): looking to mother nature

Sort by:

Citations (4)

Share this on